ID :
16098
Sat, 08/16/2008 - 09:49
Auther :
Shortlink :
http://m.oananews.org//node/16098
The shortlink copeid
ASTRAZENECA AND SINGAPORE INSTITUTIONS TO DEVELOP ANTI-CANCER COMPOUNDS
pharmaceutical companies, Friday announced it would partner with the National Cancer Centre Singapore (NCCS) and the National University Hospital (NUH) to develop anti-cancer compounds.
The partnership is to build AstraZeneca's drug development capabilities in Asia and speed up access to new medicines of potential benefit to patients withinoperable cancer, the Hepatocellular Carcinoma (HCC).
The cancer is particularly prevalent in Asia and accounts for approximately one million deaths annually worldwide, the company said, quoting medicaljournals.
A memorandum of understanding on the collaboration between the healthcarebusiness company and the NCCS and NUH was signed here today.
AstraZeneca's Oncology Therapeutic area vice president, Dr Brent Vose, said the company was committed to the research and development of new, targeted anti-cancer therapies in Asia to improve the lives of cancer patients beginningwith those affected by HCC.
He said there was a huge unmet need for treatment of liver cancer in Asia, and particularly East Asia, where there were three-quarters of the world's HCCpatients.
The collaboration work between AstraZeneca and the Singapore institutionswill involve both clinical and pre-clinical development activities.
The partnership also includes a training programme placement with the Manchester Cancer Research Centre in the UK, with whom AstraZeneca has a formalresearch alliance.
Supported in part by the Singapore Economic Development Board (SEDB), the training programme seeks to train a pool of clinical research professionals forboth private and public sector research laboratories.
SEDB's Biomedical Sciences executive director, Yeoh Keat Chuan, said AstraZeneca joined an expanding base of leading pharmaceutical and biotechnology companies that had chose to develop new drugs and therapies inSingapore.
He said it was a strong testament of Singapore's capabilities in translational and clinical research particularly in applications for diseasesprevalent in Asia.
-- BERNAMA
The partnership is to build AstraZeneca's drug development capabilities in Asia and speed up access to new medicines of potential benefit to patients withinoperable cancer, the Hepatocellular Carcinoma (HCC).
The cancer is particularly prevalent in Asia and accounts for approximately one million deaths annually worldwide, the company said, quoting medicaljournals.
A memorandum of understanding on the collaboration between the healthcarebusiness company and the NCCS and NUH was signed here today.
AstraZeneca's Oncology Therapeutic area vice president, Dr Brent Vose, said the company was committed to the research and development of new, targeted anti-cancer therapies in Asia to improve the lives of cancer patients beginningwith those affected by HCC.
He said there was a huge unmet need for treatment of liver cancer in Asia, and particularly East Asia, where there were three-quarters of the world's HCCpatients.
The collaboration work between AstraZeneca and the Singapore institutionswill involve both clinical and pre-clinical development activities.
The partnership also includes a training programme placement with the Manchester Cancer Research Centre in the UK, with whom AstraZeneca has a formalresearch alliance.
Supported in part by the Singapore Economic Development Board (SEDB), the training programme seeks to train a pool of clinical research professionals forboth private and public sector research laboratories.
SEDB's Biomedical Sciences executive director, Yeoh Keat Chuan, said AstraZeneca joined an expanding base of leading pharmaceutical and biotechnology companies that had chose to develop new drugs and therapies inSingapore.
He said it was a strong testament of Singapore's capabilities in translational and clinical research particularly in applications for diseasesprevalent in Asia.
-- BERNAMA
